Clinical Trials
295 trialsNeoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Icahn School of Medicine at Mount Sinai
ELEVATE
University of Southampton
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma
National Cancer Centre, Singapore
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
University of Michigan Rogel Cancer Center
Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy
University of Cincinnati
VEXILLUM
Spanish Oncology Genito-Urinary Group
ANICCA
University of Birmingham
CONGRATS
Institut Bergonié
HESTIA
Baylor College of Medicine
T-DXd_HER2Low
National Cancer Center Hospital East
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
China Medical University Hospital
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
MAK
Institute of Oncology Ljubljana
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
H. Lee Moffitt Cancer Center and Research Institute
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Medical University of South Carolina
METIMMOX
University Hospital, Akershus
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
City of Hope Medical Center
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
Memorial Sloan Kettering Cancer Center
Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
University of Michigan Rogel Cancer Center
DREAM3R
PrECOG, LLC.
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Big Ten Cancer Research Consortium
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)
University of California, San Francisco
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
INSPIRE
Radboud University Medical Center
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
Thomas Jefferson University
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
Wake Forest University Health Sciences
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Memorial Sloan Kettering Cancer Center
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
DICIPLE
Intergroupe Francophone de Cancerologie Thoracique
Ipilimumab and Nivolumab in Leptomeningeal Metastases
Massachusetts General Hospital
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
University of California, San Diego
Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
Medical University of South Carolina
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Washington University School of Medicine